Education
About Us
Working with TipRanks
Follow Us
DiagnoCure (DGCRF)
:DGCRF
DGCRF Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
$43.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
Mar 14, 2016Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,040,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
DGCRF FAQ
What was DiagnoCure ’s price range in the past 12 months?
DiagnoCure lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is DiagnoCure ’s market cap?
DiagnoCure ’s market cap is $43.00.
When is DiagnoCure ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were DiagnoCure ’s earnings last quarter?
Currently, no data Available
Is DiagnoCure overvalued?
According to Wall Street analysts DiagnoCure ’s price is currently Overvalued.
Does DiagnoCure pay dividends?
DiagnoCure pays a Notavailable dividend of $0.091 which represents an annual dividend yield of N/A. See more information on DiagnoCure dividends here
What is DiagnoCure ’s EPS estimate?
DiagnoCure ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DiagnoCure have?
DiagnoCure has 43,040,000 shares outstanding.
What happened to DiagnoCure ’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DiagnoCure ?
Currently, no hedge funds are holding shares in DGCRF
Company Description
DiagnoCure
9342-8530 Québec Inc., a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada. It focuses on molecular diagnostic tests for the detection and management of cancer. The company offers PCA3 test for the diagnosis of prostate cancer; and Guanylyl Cyclase C (GCC) marker and Previstage GCC colorectal cancer staging test for colorectal cancer patients, as well as PCP, a multi marker prostate cancer test. It also provides gene expression and copy number variation analysis, mutation detection, SNP genotyping, and platform and laboratory environmental services. The company was formerly known as DiagnoCure Inc. 9342-8530 Québec Inc. was founded in 1994 and is headquartered in Quebec, Canada.
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Hepion Pharmaceuticals
―
Windtree Therapeutics
―
Universe Pharmaceuticals
―